Prognostic value of serum beta(2)-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment

Autor: Anagnostopoulos, Athanasios Zervas, Konstantinos Kyrtsonis, Marie Christine Symeonidis, Argyris Gika, Dimitra Bourantas, Konstantinos Zomas, Athanasios Anagnostopoulos, Nikolaos and Pangalis, Gerasimos Dimopoulos, Meletios Athanasios Greek Myeloma Study Grp
Jazyk: angličtina
Rok vydání: 2006
Popis: Purpose: Waldenstrom’s macroglobulinemia (WM) is a lymphoplasmacytoid lymphoma characterized by a relatively indolent course with median survival ranging from 5 years to 10 years in different series. Several clinical and laboratory variables have been associated with inferior survival, such as advanced age, hyperviscosity, presence of cytopenia, and hypoalbuminemia. Recent data indicate that serum beta(2)-microglobulin (beta 2M) might also be significant. The purpose of our study was to assess possible correlations of beta 2M with clinical and laboratory variables and to further evaluate its association with cause-specific and overall survival (OS) of patients with WM requiring treatment. Patients and Methods: We analyzed 124 patients with WM with an available pretreatment value of beta 2M. Median age was 70 years (range, 28-89 years), and median survival was 105 months. Multiple clinical and laboratory parameters were evaluated for their possible correlation with OS. Results: Patients with older age, anemia, thrombocytopenia, hypoalbuminemia, and higher creatinine levels had significantly greater serum beta 2M levels. This variable was associated with impaired cause-specific survival and OS in the whole group of patients and in patients aged 4 mg/dL versus
Databáze: OpenAIRE